Several alternatives to ketamine now exist for treating depression, ranging from FDA-approved medications to brain-stimulation techniques and investigational compounds still in clinical trials. The landscape has expanded considerably since ketamine’s antidepressant effects were first documented, driven partly by the drug’s own limitations: it requires clinical supervision, can cause dissociation, and raises questions about long-term bladder and liver health. Whether you’re looking for something oral, something with fewer side effects, or something that doesn’t require repeated clinic visits, the options depend on what specifically makes ketamine a poor fit for you.
Why People Look Beyond Ketamine
Ketamine works through a mechanism that was genuinely revolutionary when researchers first noticed it. By blocking a type of receptor in the brain involved in glutamate signaling, it triggers a cascade that leads to the rapid production of a growth factor called BDNF, which in turn strengthens connections between neurons. This chain of events can lift depressive symptoms within hours rather than the weeks that conventional antidepressants typically require.1PubMed Central. Mechanisms of ketamine action as an antidepressant That speed is what makes ketamine so appealing, and it’s also why every alternative is measured against it.
But speed isn’t everything. There are practical reasons people seek something different. Ketamine is typically given intravenously or as a nasal spray in a supervised clinical setting, meaning regular time off work and travel to a clinic. It causes dissociative episodes during and shortly after infusion, which some people find deeply unpleasant. Acute side effects can include dizziness, nausea, hallucinations, and abdominal pain.2PubMed. The clinical toxicology of ketamine And for people with a history of psychosis, mania, uncontrolled high blood pressure, recent heart attack or stroke, severe liver disease, or active substance use disorders, ketamine is simply contraindicated.3AJN The American Journal of Nursing. Ketamine as a Mental Health Treatment
Chronic use also carries risks to the urinary tract. Frequent ketamine exposure can increase the risk of cystitis symptoms by three- to fourfold, causing bladder pain, reduced storage capacity, and in severe cases kidney problems. These effects are most associated with recreational-level use, but the concern carries over to anyone on a long maintenance schedule.4PubMed Central. Ketamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug
Esketamine, the Closest Relative
The most direct alternative is actually a piece of ketamine itself. Standard ketamine is a 50/50 mix of two mirror-image molecules called S-ketamine (esketamine) and R-ketamine (arketamine). Esketamine was isolated, turned into a nasal spray called Spravato, and approved by the FDA for treatment-resistant depression. It’s administered in a certified clinic under observation, similar to IV ketamine.
How does it compare to standard IV ketamine? A systematic review pooling data from multiple head-to-head studies found no statistically significant difference in response or remission rates between the two, though the numbers slightly favored IV ketamine.5PubMed Central. Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis An earlier meta-analysis was less equivocal, finding that racemic (standard) ketamine showed higher overall response and remission rates along with lower dropout rates compared to esketamine alone.6PubMed Central. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
This matters practically. Esketamine has the advantage of FDA approval and insurance coverage pathways, but it still requires clinic visits and carries similar dissociative effects. If your reason for seeking an alternative is the in-clinic burden or the dissociation itself, esketamine doesn’t solve those problems. If your reason is that you want a version with formal regulatory backing and structured safety monitoring, it’s a meaningful step up from off-label IV ketamine.
Arketamine, the Other Half
The other mirror-image molecule, R-ketamine or arketamine, is still investigational but generating real interest. Early research consistently shows that arketamine produces fewer dissociative and psychotic-like side effects compared to both esketamine and standard ketamine.7PubMed. Arketamine: a scoping review of its use in humans That’s a potentially significant advantage, because dissociation is one of the most common reasons patients discontinue ketamine-based treatments. The antidepressant efficacy data in humans is still thin, though, and arketamine is not yet approved anywhere. It’s worth knowing about as a pipeline option, but it’s not something you can walk into a clinic and receive today.
An Oral Option That Works on the Same Brain System
For many people, the most practical alternative isn’t a ketamine variant at all but a pill that acts on the same glutamate system through a different route. Dextromethorphan-bupropion, sold under the brand name Auvelity, was FDA-approved in 2022 for major depressive disorder in adults.8PubMed Central. Glutamatergic Modulators for Major Depression from Theory to Clinical Use It’s a twice-daily oral tablet you take at home, with no clinic visits or supervision required beyond normal prescriber follow-ups.
Dextromethorphan is the active ingredient in many over-the-counter cough medicines, but at the doses used here and combined with bupropion (which slows its breakdown and has its own antidepressant effects), it modulates glutamate receptors in ways that share some downstream overlap with ketamine’s mechanism. In clinical trials, patients taking dextromethorphan-bupropion saw significant improvements in depression scores compared to both placebo and bupropion alone, with meaningful changes showing up within two weeks. Remission and response rates were significantly higher than in both comparison groups.9PubMed Central. Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder
Two weeks is fast by conventional antidepressant standards but not as fast as the hours-to-days timeline of IV ketamine. Auvelity fills a middle ground: faster onset than SSRIs or SNRIs, oral and at-home convenience, but not the same-day relief that ketamine can provide. If your depression isn’t immediately dangerous and your primary goal is avoiding clinic-based treatment, this is the most accessible glutamatergic option currently available.
Zuranolone, a Different Rapid-Acting Mechanism
Not every fast-acting antidepressant works through the glutamate system. Zuranolone (brand name Zurzuvae) is an oral neuroactive steroid that works by enhancing the activity of GABA-A receptors, the brain’s main inhibitory system. It was approved for postpartum depression, where it showed rapid improvement in depressive symptoms compared to placebo, with significant differences appearing as early as day three of treatment.10PubMed. Zuranolone for the Treatment of Postpartum Depression
What’s unusual about zuranolone is the treatment course. You take it once daily for 14 days, then stop. Modeling studies suggest its onset of action is roughly ten times faster than amitriptyline and nearly 28 times faster than escitalopram, with efficacy sustained through at least four weeks after the treatment period ends.11PubMed. Modeling the efficacy of a novel antidepressant zuranolone for major depressive disorder The idea of a two-week course that produces lasting benefit, rather than indefinite daily medication, is a fundamentally different treatment model from anything else on this list.
There’s a catch: zuranolone’s approval is specifically for postpartum depression, not the broader treatment-resistant depression population that typically receives ketamine. Research into its use for major depressive disorder more generally is ongoing, but for now, it’s not a one-to-one ketamine substitute for most people seeking alternatives. If postpartum depression is what you’re dealing with, though, it’s a genuinely novel oral option with a very short treatment duration.
Psilocybin and Serotonergic Psychedelics
Psilocybin, the active compound in psychedelic mushrooms, works through an entirely different brain pathway than ketamine, primarily activating serotonin 2A receptors. The therapeutic model is also different: rather than repeated doses, psilocybin-assisted therapy typically involves one to three sessions with extensive psychological support before, during, and after.
A meta-analysis comparing the two found that psilocybin studies showed a larger correlation between the subjective experience and therapeutic improvement than ketamine studies did, suggesting the psychological content of the psilocybin experience may be more directly tied to the antidepressant outcome.12npj Mental Health Research. Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome The practical barriers are substantial, however. Psilocybin is not FDA-approved as of mid-2025. It is available in a few jurisdictions, including Oregon’s regulated service model, but access is limited and sessions are expensive. For most people, psilocybin remains a promising but not yet accessible alternative.
Brain Stimulation Approaches
If you’d prefer to avoid drugs entirely, two brain-stimulation methods are worth considering: repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT). Both have decades of evidence behind them, and both interact with the ketamine question in specific ways.
Accelerated TMS
Standard rTMS involves daily sessions over several weeks. A newer protocol, accelerated TMS (sometimes called the Stanford Neuromodulation Therapy protocol or similar intensive variants), compresses the treatment into roughly a week of multiple daily sessions. A head-to-head comparison with intranasal esketamine in treatment-resistant depression found that accelerated TMS produced higher response and remission rates at one month. Those differences narrowed and were no longer statistically significant at three and six months, suggesting the two approaches may converge over time.13PubMed. Fast-acting approaches for treatment-resistant depression: real-world comparative effectiveness of Intranasal Esketamine versus accelerated rTMS
For maintenance, rTMS on its own has shown advantages over medication alone in preventing relapse over six-, nine-, and twelve-month follow-up periods, and ECT combined with medication also outperformed medication alone.14PubMed Central. Maintenance of Noninvasive Brain Stimulation for Preventing Relapse in Depression: A Systematic Review and Meta-Analysis TMS has the advantage of being non-invasive, requiring no anesthesia, and producing minimal cognitive side effects. Its main downsides are time commitment and cost, especially for accelerated protocols.
Electroconvulsive Therapy
ECT is often treated as a last resort, but the evidence base is strong. A meta-analysis comparing ECT directly to ketamine found that ECT had a meaningful advantage in reducing depression severity, with no significant differences in serious adverse events between the two.15PubMed Central. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode A Systematic Review and Meta-analysis However, a large randomized trial published in the New England Journal of Medicine told a somewhat different story: about 55% of patients responded to ketamine versus 41% to ECT, and ketamine was found to be noninferior. ECT was associated with a measurable decrease in memory recall after three weeks of treatment that gradually recovered, while ketamine’s main side effect was dissociation.16PubMed. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
The memory question is central to why someone might choose ketamine over ECT or vice versa. A separate randomized trial found that memory scores remained stable or improved in the ketamine group while showing a decreasing pattern in the ECT group, suggesting ketamine may carry a cognitive advantage even if the antidepressant effect of ECT is at least comparable.17PubMed Central. Comparative Effect of Intravenous Ketamine and Electroconvulsive Therapy in Major Depression: A Randomized Controlled Trial If memory preservation is a priority for you, that’s a meaningful factor. If maximizing the chance of response regardless of side effects is the priority, ECT remains one of the most potent tools in psychiatry.
Investigational Compounds in the Pipeline
Beyond what’s available now, several compounds are working through the clinical trial process. Rapastinel (also known as GLYX-13) is a glutamate-modulating agent that, in human trials, produced antidepressant effects lasting at least a week after a single dose.18PubMed Central. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus Its development has hit obstacles, and it is not yet approved, but it represents an attempt to capture ketamine’s speed without the dissociation. Other investigational agents acting through glutamate or other novel pathways continue to be studied, reflecting a broader shift in psychiatric drug development toward rapid-acting mechanisms.
Sleep Deprivation Therapy
One of the more surprising entries on any list of rapid-acting antidepressant interventions is controlled sleep deprivation. A significant subset of people with major depressive disorder or bipolar depression experience robust improvement within 24 hours of a night without sleep, mediated through effects on circadian clock genes and the brain’s internal timekeeping systems.19PubMed. Mechanisms of rapid antidepressant effects of sleep deprivation therapy: clock genes and circadian rhythms The effect tends to be temporary, often reversing after the person sleeps again, but it can be extended by combining it with light therapy or sleep-phase adjustment. In clinical settings, sleep deprivation therapy is sometimes used as a bridge to get someone through an acute depressive crisis while longer-acting treatments take hold. It’s essentially free, requires no medication, and works on a timeline comparable to ketamine. The practical challenge is that staying awake all night is difficult and potentially risky for people with bipolar disorder who are prone to manic episodes.
Cost and Access Considerations
The financial picture varies enormously across these options. A cost-effectiveness analysis found that esketamine was not cost-effective compared to augmentation therapy, combination therapy, or psychotherapy at standard willingness-to-pay thresholds. Combination therapy with standard antidepressants turned out to be the most cost-effective strategy overall. Esketamine did dominate rTMS in that model, being both cheaper and more effective, while ECT came with a very high cost per unit of benefit gained compared to esketamine.20PLOS Medicine. Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study These numbers come from one health-system context and won’t map exactly onto your situation, but the general picture is consistent with what clinicians observe: esketamine is expensive, ECT is expensive but for different reasons (anesthesia, operating room time), and rTMS falls somewhere in between.
Auvelity, as an oral medication, sidesteps the clinic-visit costs entirely but can still carry a significant pharmacy price tag depending on insurance. Zuranolone’s 14-day course is expensive upfront but avoids the ongoing costs of repeated treatments. Off-label IV ketamine in private clinics is typically paid out of pocket, running into hundreds of dollars per session with sessions needed every few weeks for maintenance.
The Addiction Question
Ketamine’s status as a recreational drug raises reasonable concerns about addiction during therapeutic use. A systematic review examining this question across more than 2,000 patients found that clear signs of tolerance to the antidepressant effect or dependence on the drug appeared in only four patients out of the entire pool.21Sage Journals (Journal of Psychopharmacology). Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature That’s reassuring but not zero, and the clinical context matters. Recreational ketamine use involves much higher and more frequent doses than therapeutic protocols. Still, if you have a personal or family history of substance use disorders, this is a legitimate reason to prefer a non-ketamine option like Auvelity, zuranolone, or brain stimulation, all of which carry no meaningful abuse potential.
Choosing Based on Your Specific Situation
The right alternative depends on what’s driving you away from ketamine in the first place. A rough framework:
- Dissociation bothers you: Arketamine (when available) shows fewer dissociative effects. Auvelity, zuranolone, and rTMS avoid dissociation entirely.
- You want something oral and at-home: Auvelity is the only currently approved option that checks both boxes for general depression. Zuranolone does the same for postpartum depression.
- You need the fastest possible relief: ECT and accelerated TMS can match or exceed ketamine’s speed. Sleep deprivation therapy works within a day but is temporary.
- You’re worried about long-term side effects: rTMS has the mildest side-effect profile of any option here. Auvelity’s side effects resemble those of standard antidepressants.
- Cost is the primary barrier: Combination or augmentation strategies with conventional antidepressants remain the most cost-effective approaches overall, even if they act more slowly.
- You have a contraindication to ketamine: Most alternatives except esketamine and arketamine sidestep ketamine’s specific contraindications, though each has its own. ECT, for instance, requires general anesthesia, which carries its own exclusions.
Conventional antidepressants still deserve mention here. Some, like mirtazapine and venlafaxine, can show early partial response within the first one to two weeks, which is faster than the typical four-to-six-week expectation many people carry.22Journal of Affective Disorders Reports. Rapid response to antidepressants and correlation with response and remission after acute treatment They’re not ketamine-fast, but they’re also not as slow as their reputation suggests, and they remain the most thoroughly studied and widely accessible treatments available. For someone whose depression is not immediately treatment-resistant, optimizing or switching conventional agents is often the most reasonable first move before considering any of the options above.